Beclomethasone
As of the edition of 20 October 2026, Beclomethasone is a small molecule: marketed, first approved in 1968 (ES); acts on NR3C1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Becotide
- First approved
- 1 January 1968 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- GSK; 2 holders in all
- Registered trials
- 27, 4 stopped early
- Disease areas
- Lungs and airways; Immune system; Ear, nose and throat; Infections; Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Beclomethasone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 6 | 0 | 0 |
| Phase 3 | 8 | 6 | 0 | 1 |
| Phase 4 | 10 | 5 | 0 | 3 |
| All trials | 27 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Organon | Lead sponsor of trials | 1995 to now |
| Chiesi Farmaceutici | Lead sponsor of trials | 2002 to now |
| Azidus Brasil | Lead sponsor of trials | 2007 to now |
| Soligenix | Lead sponsor of trials | 2009 to now |
| Bitop | Lead sponsor of trials | 2011 to now |
| New York City Health and Hospitals | Lead sponsor of trials | 2017 to now |